Our Firm

Our Firm

Green Griffith is a preeminent intellectual property law firm, uniquely qualified to assist small and mid-sized pharmaceutical and biotech companies protect their most valuable assets and position them for future success.
Learn More >
Our Team

Our Team

Our technical knowledge makes the difference: all of our attorneys have degrees in pharma-related fields, including organic chemistry, chemical engineering and molecular biology, and many have advanced degrees.
Learn More >
Our Clients

Our Clients

Our clients are both generics and brand, small and mid-sized pharmaceutical and biotech companies, focused on securing market position and/or overcoming obstacles to new product entry for their drugs and therapies.​​
Learn More >

News and Insights

FTC and TEVA Reach Settlement in Reverse-Payment Antitrust Litigation

The FTC has reached settlement with TEVA Pharmaceuticals in three antitrust lawsuits addressing reverse-payment settlement agreements in patent c…
Read More >

Federal Circuit: USPTO Incorrectly Calculates Patent Term Adjustment (PTA)

In a January 23, 2019, opinion, the Federal Circuit determined that the U.S. Patent and Trademark Office (USPTO) improperly calculates patent ter…
Read More >

Chris Griffith Speaks at 9th Asia Pharma R&D Leaders Conference

This event provided a strategic platform for companies, academia and other stakeholders in the Asia biopharma industry to meet, communicate and e…
Read More >

US Supreme Court Decides that a “Secret” Sale or Offer for Sale of a Claimed Invention is Invalidating Prior Art Under the AIA

The US Supreme Court in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., determined that because Congress retained the prior “on…
Read More >